Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03224312

Chongqing Primary Aldosteronism Study

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Aldosteronism Adrenal Gland Diseases Adrenocortical Hyperfunction Endocrine System Diseases Hyperaldosteronism

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study will include the subjects of a series of studies on hypertension conducted by our team, including essential hypertension, PA subjects, and establish a large sample database and specimen bank through follow-up and omics analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hypertensive patients who completed ARR screening and necessary further tests;
  • Voluntary to sign the informed consent.

Exclusion criteria

  • patients with severe cardiac, hepatic or renal dysfunction;
  • suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

  1. numbers of patients who develop cardiovascular events

    Time frame: 1-15 years

    compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension

Secondary outcomes

  1. estimated glomerular filtration rate (eGFR)

    Time frame: 1-15 years

    Compare the incidence of hypertensive nephropathy between two groups (based on eGFR)

  2. The incidence of new atrial fibrillation

    Time frame: 1-15 years

    Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension

  3. The incidence of left ventricular hypertrophy

    Time frame: 1-15 years

    Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension

  4. the variation of carotid intima-media thickness

    Time frame: 1-15 years

    Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension

  5. subgroup analysis of cardiovascular events

    Time frame: 1-15 years

    Compare the cardiovascular and cerebrovascular risk between unilateral PA and idiopathic bilateral adrenal hyperplasia

  6. quality of life score

    Time frame: 1-15 years

    Compare the quality of life between unilateral PA and idiopathic bilateral adrenal hyperplasia by the questionnaire.

  7. Cardiovascular risk score

    Time frame: 1-15 years

    To investigate what kind of cardiovascular risk score can better predict cardiovascular risk of PA

Study contacts

Contact information is provided by the study sponsor or research team.

Qifu Li, phD

CONTACT

[email protected]

+86 023-89011552

Shumin Yang, phD

CONTACT

[email protected]

+86 023-89011552

Sponsors and collaborators

Lead sponsor

Chongqing Medical University

Other

Registry information

Important dates

Study start
2016
Primary completion
2027
Study completion
2028
First posted
Jul 21, 2017
Registry last updated
Sep 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.